Atrial septal defect migraine: Difference between revisions
Jump to navigation
Jump to search
(New page: {{CMG}} ==Migraine== Some recent research has suggested that a proportion of cases of migraine may be caused by patent foramen ovale. While the exact mechanis...) |
No edit summary |
||
| Line 6: | Line 6: | ||
--><ref>{{cite journal | author = Azarbal B, Tobis J, Suh W, Chan V, Dao C, Gaster R | title = Association of interatrial shunts and migraine headaches: impact of transcatheter closure. | journal = J Am Coll Cardiol | volume = 45 | issue = 4 | pages = 489-92 | year = 2005 | id = PMID 15708691}}</ref> | --><ref>{{cite journal | author = Azarbal B, Tobis J, Suh W, Chan V, Dao C, Gaster R | title = Association of interatrial shunts and migraine headaches: impact of transcatheter closure. | journal = J Am Coll Cardiol | volume = 45 | issue = 4 | pages = 489-92 | year = 2005 | id = PMID 15708691}}</ref> | ||
This remains controversial. 20% of the general population have a [[PFO]], which for the most part, is asymptomatic. 20% of the female population have migraines. And, the [[placebo effect]] in migraine typically averages around 40%. The high frequency of these facts makes statistically significant relationships between [[PFO]] and migraine difficult (i.e., the relationship may just be chance or coincidence). | This remains controversial. 20% of the general population have a [[PFO]], which for the most part, is asymptomatic. 20% of the female population have migraines. And, the [[placebo effect]] in migraine typically averages around 40%. The high frequency of these facts makes statistically significant relationships between [[PFO]] and migraine difficult (i.e., the relationship may just be chance or coincidence). | ||
==Medical therapy for migraines== | |||
Although there is no direct evidence to link migraines and atrial septal defects, some research has noted that treatment of [[Atrial septal defect patent foramen ovale|patent foramen ovale]] can reduce the severity of migraine symptoms.<!-- | |||
--><ref>{{cite journal | author = Adams H | title = Patent foramen ovale: paradoxical embolism and paradoxical data. | journal = Mayo Clin Proc | volume = 79 | issue = 1 | pages = 15-20 | year = 2004 | id = PMID 14708944}}</ref><!-- | |||
--><ref>{{cite journal | author = Azarbal B, Tobis J, Suh W, Chan V, Dao C, Gaster R | title = Association of interatrial shunts and migraine headaches: impact of transcatheter closure. | journal = J Am Coll Cardiol | volume = 45 | issue = 4 | pages = 489-92 | year = 2005 | id = PMID 15708691}}</ref> | |||
Effective pharmacologic therapies for migraine prevention include: | |||
*Anti-hypertensives: beta blockers (propranolo, timolo, metoprolol, nadolol, and atenolol), calcium channel blockers (verapamil, nifedipine, and nimodipine), and angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (lisinopril, candesartan) | |||
*Anti-depressants: amitriptyline, venlafaxine, nortriptyline, doxepin, protriptyline | |||
*Anti-convulsants: valproate, gabapentin, topiramate | |||
*Other prophylaxis: botuliunum toxin, butterbur, coenzyme Q10, feverfew, magnesium, methysergide, opioids, pizotifen, riboflavin | |||
==References== | ==References== | ||
| Line 13: | Line 24: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 13:26, 5 July 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Migraine
Some recent research has suggested that a proportion of cases of migraine may be caused by patent foramen ovale. While the exact mechanism remains unclear, closure of a PFO can reduce symptoms in certain cases.[1][2] This remains controversial. 20% of the general population have a PFO, which for the most part, is asymptomatic. 20% of the female population have migraines. And, the placebo effect in migraine typically averages around 40%. The high frequency of these facts makes statistically significant relationships between PFO and migraine difficult (i.e., the relationship may just be chance or coincidence).
Medical therapy for migraines
Although there is no direct evidence to link migraines and atrial septal defects, some research has noted that treatment of patent foramen ovale can reduce the severity of migraine symptoms.[3][4]
Effective pharmacologic therapies for migraine prevention include:
- Anti-hypertensives: beta blockers (propranolo, timolo, metoprolol, nadolol, and atenolol), calcium channel blockers (verapamil, nifedipine, and nimodipine), and angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (lisinopril, candesartan)
- Anti-depressants: amitriptyline, venlafaxine, nortriptyline, doxepin, protriptyline
- Anti-convulsants: valproate, gabapentin, topiramate
- Other prophylaxis: botuliunum toxin, butterbur, coenzyme Q10, feverfew, magnesium, methysergide, opioids, pizotifen, riboflavin
References
- ↑ Adams H (2004). "Patent foramen ovale: paradoxical embolism and paradoxical data". Mayo Clin Proc. 79 (1): 15–20. PMID 14708944.
- ↑ Azarbal B, Tobis J, Suh W, Chan V, Dao C, Gaster R (2005). "Association of interatrial shunts and migraine headaches: impact of transcatheter closure". J Am Coll Cardiol. 45 (4): 489–92. PMID 15708691.
- ↑ Adams H (2004). "Patent foramen ovale: paradoxical embolism and paradoxical data". Mayo Clin Proc. 79 (1): 15–20. PMID 14708944.
- ↑ Azarbal B, Tobis J, Suh W, Chan V, Dao C, Gaster R (2005). "Association of interatrial shunts and migraine headaches: impact of transcatheter closure". J Am Coll Cardiol. 45 (4): 489–92. PMID 15708691.